Q linea AB (QLINEA) - Total Assets
Based on the latest financial reports, Q linea AB (QLINEA) holds total assets worth Skr369.67 Million SEK (≈ $39.78 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Q linea AB's book value for net asset value and shareholders' equity analysis.
Q linea AB - Total Assets Trend (2015–2025)
This chart illustrates how Q linea AB's total assets have evolved over time, based on quarterly financial data.
Q linea AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Q linea AB's total assets of Skr369.67 Million consist of 89.2% current assets and 10.8% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr258.11 Million | 69.8% |
| Accounts Receivable | Skr38.19 Million | 10.3% |
| Inventory | Skr30.68 Million | 8.3% |
| Property, Plant & Equipment | Skr32.72 Million | 8.9% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr4.89 Million | 1.3% |
Asset Composition Trend (2015–2025)
This chart illustrates how Q linea AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see QLINEA company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Q linea AB's current assets represent 89.2% of total assets in 2025, an increase from 59.7% in 2015.
- Cash Position: Cash and equivalents constituted 69.8% of total assets in 2025, up from 9.5% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 16.0% in 2015.
- Asset Diversification: The largest asset category is cash and equivalents at 69.8% of total assets.
Q linea AB Competitors by Total Assets
Key competitors of Q linea AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.15 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS
|
USA | $139.92 Million |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO
|
India | Rs8.57 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
|
Aligned Genetics Inc
KQ:238120
|
Korea | ₩45.11 Billion |
|
Heramed Ltd
AU:HMD
|
Australia | AU$1.04 Million |
|
Acarix A/S
ST:ACARIX
|
Sweden | Skr48.33 Million |
Q linea AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.07 | 0.75 | 6.68 |
| Quick Ratio | 10.04 | 0.49 | 6.25 |
| Cash Ratio | 8.66 | 0.20 | 0.00 |
| Working Capital | Skr300.06 Million | Skr-32.50 Million | Skr215.44 Million |
Q linea AB - Advanced Valuation Insights
This section examines the relationship between Q linea AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.32 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | 149.8% |
| Total Assets | Skr369.67 Million |
| Market Capitalization | $34.46 Million USD |
Valuation Analysis
Below Book Valuation: The market values Q linea AB's assets below their book value (0.09x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Q linea AB's assets grew by 149.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Q linea AB (2015–2025)
The table below shows the annual total assets of Q linea AB from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr369.67 Million ≈ $39.78 Million |
+149.79% |
| 2024-12-31 | Skr147.99 Million ≈ $15.93 Million |
-36.20% |
| 2023-12-31 | Skr231.98 Million ≈ $24.96 Million |
+11.86% |
| 2022-12-31 | Skr207.39 Million ≈ $22.32 Million |
-55.56% |
| 2021-12-31 | Skr466.63 Million ≈ $50.22 Million |
+13.20% |
| 2020-12-31 | Skr412.23 Million ≈ $44.36 Million |
+10.10% |
| 2019-12-31 | Skr374.41 Million ≈ $40.29 Million |
-30.55% |
| 2018-12-31 | Skr539.07 Million ≈ $58.01 Million |
+2830.20% |
| 2017-12-31 | Skr18.40 Million ≈ $1.98 Million |
+9.11% |
| 2016-12-31 | Skr16.86 Million ≈ $1.81 Million |
+20.76% |
| 2015-12-31 | Skr13.96 Million ≈ $1.50 Million |
-- |
About Q linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, European Union, the Middle East, and the United States. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, includin… Read more